Ultimovacs
Menu Close ✕
  • About
    • About Ultimovacs
    • Team
    • Board of directors
  • Technology
    • Technology overview
    • Immunotherapy
    • Clinical studies
  • Investors
    • Shares
    • Financial reports
    • Presentations and Publications
    • Investor relations contacts
    • Analyst coverage
    • Governance
    • News
  • Contact

Enabling the immune system to fight cancer

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.

Read more about Ultimovacs

Our mission is to extend and improve the life of patients by directing the immune system against the core of cancer.

We will provide universally accessible solutions.

Tweets | @Ultimovacs

See all

Press Releases

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program 4, June, 2021
Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma 1, June, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 28, May, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 25, May, 2021
Ultimovacs ASA: Mandatory notification of trade by primary insider 20, May, 2021
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data 19, May, 2021
See all

News

Biostock article on Ultimovacs’ clinical data presented at ASCO 8, June, 2021
ASCO data – HealthTalk interview with CMO Jens Bjørheim 7, June, 2021
Company update on Ultimovacs after the release of clinical data, has been published by Edison Investment Research 21, May, 2021
Article in Dagens Medisin 21, May, 2021
Article in HealthTalk regarding the phase I data i MM 21, May, 2021
BioStock article: “New data gives weight to Ultimovacs’s cancer vaccine” 20, May, 2021
Upcoming events 10, May, 2021
See all
E-mail: mail@ultimovacs.com
Phone number: +47 413 80 080
Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

  • Technology
  • Clinical studies
  • Immunotherapy

Ultimovacs

  • About Ultimovacs
  • Team
  • Board of directors
  • Contact us

Investors

  • Share information
  • Financial reports
  • Investor relations contacts
  • News
Copyright © Ultimovacs ASA 2021